Close Menu

NEW YORK – Exact Sciences and the Mayo Clinic announced today that they have initiated a study to analyze the real-world impact of the company's Cologuard colorectal cancer diagnostic test on colorectal cancer screening, incidence, and mortality rates.

The Voyage study is a prospective, observational study designed to enroll more than 150,000 people with a valid Cologuard order. The researchers will follow participants for at least seven years to evaluate clinical outcomes, Exact said.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.